Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.78 |
| ▸ | MEN1 | O00255 | 5/20 | 0.78 |
| ▸ | MAPT | P10636 | 5/20 | 0.78 |
| ▸ | GAA | P10253 | 4/20 | 0.78 |
| ▸ | POLB | P06746 | 3/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.78 |
| ▸ | PKM | P14618 | 1/20 | 0.78 |
| ▸ | RECQL | P46063 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | USP7 | Q93009 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | CA9 | Q16790 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.65 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.65 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14582287 | 0.90 | KMT2A (0.80) | ARKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL914607 | 0.88 | AR (0.81) | ARKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL12700987 | 0.88 | AR (0.74) | ARKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL14129132 | 0.85 | L3MBTL1 (0.72) | ARKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL21105376 | 0.84 | KMT2A (0.70) | ARKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL917688 | 0.83 | GPER1 (0.79) | ARKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL20506682 | 0.83 | GPER1 (0.79) | ARKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL12700990 | 0.81 | AR (0.65) | ARKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL681674 | 0.80 | MAPT (0.81) | ARKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL21105585 | 0.80 | GPER1 (0.71) | ARKMT2AALDH1A1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210186936-A1 | METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY | UNM RAINFOREST INNOVATIONS | 2021-06-24 | — | — | US | disclosed |
| US-10980785-B2 | Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity | UNM RAINFOREST INNOVATIONS (US) | 2021-04-20 | — | — | US | disclosed |
| US-10682341-B2 | Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity | STC.UNM (US) | 2020-06-16 | — | — | US | disclosed |
| US-20200113875-A1 | METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY | UNM RAINFOREST INNOVATIONS | 2020-04-16 | — | — | US | disclosed |
| US-10471047-B2 | Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity | STC.UNM (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190160047-A1 | METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY | UNM RAINFOREST INNOVATIONS | 2019-05-30 | — | — | US | disclosed |
| US-10251870-B2 | Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity | STC.UNM (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180055826-A1 | METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY | UNM RAINFOREST INNOVATIONS | 2018-03-01 | — | — | US | disclosed |
| US-20180055826-A1 | METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY | UNM RAINFOREST INNOVATIONS | 2018-03-01 | — | — | US | disclosed |
| WO-2016144647-A1 | METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY | STC.UNM (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20110092533-A1 | COMPOUNDS FOR BINDING TO ER ALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | STC. UNM (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092533-A1 | COMPOUNDS FOR BINDING TO ER ALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | STC. UNM (US) | 2011-04-21 | — | — | US | disclosed |
| US-7875721-B2 | Modulators of estrogen receptor alpha/beta G protein-coupled receptor 30, e.g., 1-(4-(6-Bromo-benzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)1-ethanone; treating diseases such as cancer, neurodegenerative disorders, obesity, osteoporosis, and symptoms of menopause | STC.UNM (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875721-B2 | Modulators of estrogen receptor alpha/beta G protein-coupled receptor 30, e.g., 1-(4-(6-Bromo-benzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)1-ethanone; treating diseases such as cancer, neurodegenerative disorders, obesity, osteoporosis, and symptoms of menopause | STC.UNM (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875721-B2 | Modulators of estrogen receptor alpha/beta G protein-coupled receptor 30, e.g., 1-(4-(6-Bromo-benzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)1-ethanone; treating diseases such as cancer, neurodegenerative disorders, obesity, osteoporosis, and symptoms of menopause | STC.UNM (US) | 2011-01-25 | — | — | US | disclosed |
| US-20080167334-A1 | Compounds for binding to ERalpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | ARROWHEAD CENTER, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20080167334-A1 | Compounds for binding to ERalpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | ARROWHEAD CENTER, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20080167334-A1 | Compounds for binding to ERalpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | ARROWHEAD CENTER, INC. | 2008-07-10 | — | — | US | disclosed |
| WO-2007019180-A2 | COMPOUNDS FOR BINDING TO ERALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | SCIENCE & TECHNOLOGY CORPORATION @ UNM (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019180-A2 | COMPOUNDS FOR BINDING TO ERALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | SCIENCE & TECHNOLOGY CORPORATION @ UNM (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10682341-B2 | Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity | GPER1, NOX4, GPR119 | AR 224/4885KMT2A 3431/4885ALDH1A1 1153/4885 |
| US-20210186936-A1 | METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY | GPER1, NOX4, GPR119 | AR 224/4885KMT2A 3431/4885ALDH1A1 1153/4885 |
| US-20190160047-A1 | METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY | GPER1, NOX4, GPR119 | AR 224/4885KMT2A 3431/4885ALDH1A1 1153/4885 |
| US-20180055826-A1 | METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY | GPER1, NOX4, GPR119 | AR 224/4885KMT2A 3431/4885ALDH1A1 1153/4885 |
| US-10980785-B2 | Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity | GPER1, NOX4, GPR119 | AR 224/4885KMT2A 3431/4885ALDH1A1 1153/4885 |
| US-20110092533-A1 | COMPOUNDS FOR BINDING TO ER ALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | GPER1, ESR2, ESRRG | AR 49/4885KMT2A 4342/4885ALDH1A1 2014/4885 |
| US-20080167334-A1 | Compounds for binding to ERalpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | GPER1, ESR2, ESRRG | AR 56/4885KMT2A 4138/4885ALDH1A1 1647/4885 |
| US-10251870-B2 | Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity | GPER1, NOX4, GPR119 | AR 224/4885KMT2A 3431/4885ALDH1A1 1153/4885 |
| US-10471047-B2 | Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity | GPER1, NOX4, GPR119 | AR 224/4885KMT2A 3431/4885ALDH1A1 1153/4885 |
| US-20200113875-A1 | METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY | GPER1, NOX4, GPR119 | AR 224/4885KMT2A 3431/4885ALDH1A1 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.